RE:Tick, tick, tick…. That is a Canadian/France patent. Not sure where you see a reference to TFC-039?
"Another object of this invention is a compound as defined above, for use as a drug, in particular as an inhibitor of the sodium-dependent glucose co-transporter, such as SGLT1, SGLT2 and SGLT3.
Within the meaning of this invention, "inhibitor of the sodium-dependent glucose co-transporter" is understood to mean a compound capable of inhibiting partially or totally the sodium-dependent glucose co-transporter.
More particularly, the compounds of the invention may be used for treating diabetes, and more particularly type-II diabetes, diabetes-related complications, such as arteritis of the lower extremities, cardiac infarction, renal insufficiency, neuropathy or blindness, hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, X
syndrome and arteriosclerosis.
The compounds of the invention may likewise be used as an anti-cancer, anti-infective, anti-viral, anti-thrombotic or anti-inflammatory drug.
The invention likewise relates to the use of a compound of the invention for the manufacture of a drug intended for the treatment of diabetes, and more particularly type-II diabetes, diabetes-related complications, such as arteritis of the lower extremities, cardiac infarction, renal insufficiency, neuropathy or blindness, hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, X syndrome and arteriosclerosis, as well as for the manufacture of an anti-cancer, anti-infective, anti-viral, anti-thrombotic or anti-inflammatory drug.
The invention likewise relates to a method for a treatment against diabetes, and more particularly type-II diabetes, diabetes-related complications, such as arteritis of the lower extremities, cardiac infarction, renal insufficiency, neuropathy or blindness, hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, X syndrome and arteriosclerosis, as well as for an anti-cancer, anti-infective, anti-viral, anti-thrombotic or anti-inflammatory treatment, including the administration of at least one compound of the invention to a patient in need thereof.
Silylated compounds of the present invention, as well as compounds with R =
CH20Bn, R1 = OBn, R2 = OBn and/or R3 = OBn, will not be preferred for their use as medicament.
Another object of this invention is a pharmaceutical or cosmetic composition including at least one compound of the invention as defined above and at least one pharmaceutically or cosmetically acceptable vehicle.
In this invention, "cosmetically acceptable" is understood to mean what is useful in the preparation of a cosmetic composition which is generally safe, non-toxic and neither biologically nor otherwise undesirable and which is acceptable for veterinary as well as human cosmetic use.
The compounds according to the invention can be administered orally, sublingually, parenterally, subcutaneously, intramuscularly, intravenously, transdermally, locally or rectally."
USPTO:
| Invention title/Inventor C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY
Graldine Castelot-Deliencourt-Godefroy | Patent 8486897
Jul 16, 2013 | Publication 20110034402
Feb 10, 2011 | Application 12935468
Sep 29, 2010 | PCT |
This invention relates to a family of fluorinated C-aryl glycoside compounds, the process for their preparation, as well as the application of same in the pharmaceutical and cosmetics fields, in particular for the treatment of diabetes and obesity.
Sugars and the derivatives thereof constitute one of the most common classes of compounds in nature. Based on their chemical structures, they exhibit various physicochemical properties and can play a key role in a wide variety of biological processes.
In recent years, there has been a growing interest in discovering new glycosides having advantageous properties in terms of improved efficacy, selectivity and stability.
Found among these compounds, in particular, are aryl glycosides or phenol glycosides having applications in the field of cosmetics or in the treatment or prevention of diseases such as diabetes, obesity, cancer, inflammatory diseases, auto-immune diseases, infections, thromboses, and with regard to numerous other therapeutic fields. By their biological properties and their structure, these compounds interest numerous research teams.